Markers of thrombosis and hemostasis in acute coronary syndromes: Relationship to increased heart rate and reduced heart-rate variability

Clinical Cardiology

Volumn 32, Issue 4, 2009, Pages 204-209

  Hamaad, Ali ^a   Sosin, Michael D ^a   Blann, Andrew D ^a   Lip, Gregory Y H ^a   MacFadyen, Robert J ^a,b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CD40 LIGAND; CLOPIDOGREL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HEART RATE; HEART RATE VARIABILITY; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; RR INTERVAL; THROMBOSIS;

ACUTE CORONARY SYNDROME; ARRHYTHMIAS, CARDIAC; CASE-CONTROL STUDIES; CORONARY THROMBOSIS; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PROSPECTIVE STUDIES; VON WILLEBRAND FACTOR;

EID: 64949130626     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20321     Document Type: Article

References (33)

1. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996;93(5):1043-1065.
2. Tsuji H, Vendetti FJ Jr, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort: the Framingham Heart Study. Circulation. 1994;90: 878-883.
3. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ, The Multicenter Post- Infarction Research Group. Decreased heart rate variability and its association with increased mortality after myocardial infarction. Am J Cardiol. 1987;59:256-262.
4. Lombardi F, Sandrone G, Pernpruner S, et al. Heart rate variability as an index of sympathovagal interaction after acute myocardial infarction. Am J Cardiol. 1987;60:1239-1245.
5. Beere PA, Glagov S, Zarins CK Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984;226:180-182.
6. Sajadieh A, Nieslen OW, Rasmussen V, et al. Increased heart rate and reduced heart rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J. 2004;25:363-370.
7. Cucuiano MP, Cristea A, Roman S, et al. Comparative behaviour of the components of the factor VIII complex in acute myocardial infarction. Thromb Res. 1983;30: 487-497.
8. Hillis GS, Terregino C, Taggart P, et al. Elevated soluble P-selectin levels are associated with an increased risk of adverse events in patients with presumed myocardial ischaemia. Am Heart J. 2002;142:235-241.
9. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40-ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111.
10. Lew AS, Berberian L, Cercek B, et al. Elevated serum D-dimer: a degradation product of cross-linked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction. JAm Coll Cardiol. 1986;7:1320-1324.
11. O'Brien JR. Some effects of adrenaline and anti-adrenaline on platelets in vitro and vivo. Nature. 1963;200:763-764.
12. Lalau Keraly C, Kinlogh-Rathbone RL, Packham MA, Suzuki H, Mustard JF. Conditions affecting the response of human platelets to epinephrine. Thromb Haemost. 1988;60:209-216.
13. Larsson PT, Hjemdahl P, Olsson G, Angelin B, Hornstra G Platelet aggregability in humans: contrasting in-vivo and in-vitro findings during sympathoadrenal activation and relationship to serum lipids. Eur J Clin Invest. 1990;20:398-405.
14. Siess W, Lorenz R, Roth P, Weber PC. Plasma catecholamines, platelet aggregation and associated thromboxane formation after physical exercise, smoking or norepinephrine infusion. Circulation. 1982;66:44-48.
15. Arkel YS, Haft JI, Kreutner W, Sherwood J, Williams R. Alteration in second phase platelet aggregation associated with an emotionally stressful activity. Thromb Haemost. 1977;38:552-561.
16. Mehta J, Mehta P, Pepine CJ. Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease: role of tachycardia, stress and propranolol. Circulation. 1978;58:881-886.
17. Mikhailidis DP, Barradas MA, Mier A, etal. Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology. 1987;38:36-45.
18. Ogston D, McDonald GA, Fullerton HW. The influence of anxiety in tests of blood coagulability and fibrinolytic activity. Lancet. 1962;2:521-523.
19. Cash JD, Allan AGE. Effect of mental stress on the fibrinolytic reactivity to exercise. Br Med J. 1967;2:545-548.
20. Cash JD, Woodfield DG, Allan AG. Adrenergic mechanisms in the systemic plasminogen activator response to epinephrine in man. Br J Haematol. 1970;18:487-494.
21. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-969.
22. Kayikcioglu M, Can L, Mete-Erdem N, et al. Soluble P-selectin and the success of thrombolysis in acute myocardial infarction. Int J Cardiol. 2001;79:223-229.
23. Mulvihill N, Foley JB, Ghaisas N, et al. Early temporal expression of soluble cellular adhesion molecules in patients with unstable angina and subendocardial myocardial infarction. Am J Cardiol. 1999;83:1265-1267.
24. 40-ligand/CD154 on platelets. Heart. 2001;86:649-655.
25. Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J. 1993;126:1299-1304.
26. Liuozzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
27. Casolo GC, Strode P, Sigorini C, et al. Heart rate variability during the acute phase of myocardial infarction. Circulation. 1992;85(6):2073-2079.
28. Bigger JT Jr, Fleiss JL, Rolnitzky LM, Steinman RC, Scneider WJ. Time course of recovery of heart period variability after myocardial infarction. J Am Coll Cardiol. 1991;18:1643-1649.
29. Hamaad A, Sosin M, Blann AD, et al. Markers of inflammation in acute coronary syndromes: associations with increased heart rate and reductions in heart rate variability. Clin Cardiol. 2005; 28:570-576.
30. Bacon SL, Ring C, Hee FL, etal. Haemodynamic, haemostatic, and endothelial reactions to psychological and physical stress in coronary artery disease patients. Biol Psychol. 2006;71: 162-170.
31. Lee KW, Blann AD, Ingram J, Jolly K, Lip GYH. Incremental shuttle walking is associated with activation of haemostatic and haemorrheological markers in patients with coronary artery disease: the Birmingham rehabilitation uptake maximisation study (BRUM). Heart. 2005;91:1413-1417.
32. 40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999; 100:614-620.
33. Nolan J, Batin PD, Andrews R, etal. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-HEART). Circulation. 1998;98: 1510-1516.